Search - tctmd.com

Displaying 1 - 20 of 40

Sort: Relevancy | Date

February 2025 Dispatch for the CV Team

News Opinion CV Team Dispatch

February 2025 Dispatch for the CV Team

February 01, 2025

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

News Conference News ESC 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Michael O'Riordan

September 06, 2023

CV Care Around Noncardiac Surgery: New ESC Guidelines

News Conference News ESC 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

Michael O'Riordan

September 07, 2022

Managing AF Patients Undergoing PCI—Some Lingering Questions

News Conference News ACC 2022

Managing AF Patients Undergoing PCI—Some Lingering Questions

Michael O'Riordan

April 12, 2022

Roughly 80% of ESC Guideline Writers Have Financial COIs

News Features

Roughly 80% of ESC Guideline Writers Have Financial COIs

Michael O'Riordan

April 01, 2021

Gatekeeper CTA Strategy in Stable Chest Pain Still Needs Honing

News Daily News

Gatekeeper CTA Strategy in Stable Chest Pain Still Needs Honing

Yael L. Maxwell

March 08, 2021

New European NSTE ACS Guidelines Embrace hs-Troponin, CTA, NOAC Trials

News Conference News ESC 2020

New European NSTE ACS Guidelines Embrace hs-Troponin, CTA, NOAC Trials

September 03, 2020

New Meta-analysis Supports NOAC Plus P2Y12 Inhibitor for PCI in A-fib

News Daily News

New Meta-analysis Supports NOAC Plus P2Y12 Inhibitor for PCI in A-fib

February 28, 2020

Some A-fib Patients May Need a Bit More Aspirin After PCI: AUGUSTUS

News Conference News AHA 2019

Some A-fib Patients May Need a Bit More Aspirin After PCI: AUGUSTUS

November 20, 2019

TCTMD’s Top 10 Most Popular Stories for September 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2019

October 01, 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

News Conference News TCT 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

September 26, 2019

Field in Flux: What’s the Best Antithrombotic Strategy for A-fib Patients Undergoing PCI?

News Daily News

Field in Flux: What’s the Best Antithrombotic Strategy for A-fib Patients Undergoing PCI?

Michael O'Riordan

July 03, 2019

AUGUSTUS: Apixaban Plus P2Y12 Inhibitor the Best Combo in A-fib Patients With ACS or Undergoing PCI

News Conference News ACC 2019

AUGUSTUS: Apixaban Plus P2Y12 Inhibitor the Best Combo in A-fib Patients With ACS or Undergoing PCI

March 17, 2019

Stay Away From Warfarin-Based Triple Therapy in Patients With A-fib and CAD, Study Affirms

News Daily News

Stay Away From Warfarin-Based Triple Therapy in Patients With A-fib and CAD, Study Affirms

October 03, 2018

TCTMD’s Top 10 Most Popular Stories for August 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2018

September 04, 2018

New ESC/EACTS Revascularization Guidelines Make Room for Radial First, STICH, and DES for All

News Conference News ESC 2018

New ESC/EACTS Revascularization Guidelines Make Room for Radial First, STICH, and DES for All

Michael O'Riordan

August 29, 2018

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

News Daily News

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

Michael O'Riordan

July 31, 2018

NOACs Carry Lower MI Risk vs Warfarin in Real-world Study

News Daily News

NOACs Carry Lower MI Risk vs Warfarin in Real-world Study

June 25, 2018

TCTMD’s Top 10 Most Popular Stories for March 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for March 2018

April 02, 2018

ACC 2018, Day Three: Gout, Hypertension, and Diabetes Dominate Opening Late Breaker

News Conference News ACC 2018

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

March 12, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.